Invivyd Loss Submission Form

The filed complaint alleges that Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that:

(a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants’ claims regarding ADG20’s efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.